OncoMatch/Clinical Trials/NCT05999994
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Is NCT05999994 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for neoplasms.
Treatment: Ramucirumab · Cyclophosphamide · Vinorelbine · Gemcitabine · Docetaxel · Abemaciclib · Irinotecan · Temozolomide — The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Demographics
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate organ function
Liver function
adequate organ function
adequate hematologic and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Childrens Hospital of Alabama · Birmingham, Alabama
- Phoenix Children's Hospital · Phoenix, Arizona
- Phoenix Children's Hospital · Phoenix, Arizona
- Childrens Hospital of Los Angeles · Los Angeles, California
- UCLA Medical Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05999994 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 39 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify